An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer
Abstract Dexamethasone has antitumor activity in metastatic castration resistant prostate cancer (mCRPC). We aimed to investigate intravenous liposome‐encapsulated dexamethasone disodium phosphate (liposomal dexamethasone) administration in mCRPC patients. In this exploratory first‐in‐man study, pat...
Enregistré dans:
Auteurs principaux: | Josephina P. M. Vrouwe, Ingrid M. C. Kamerling, Michiel J. vanEsdonk, Josbert M. Metselaar, Frederik E. Stuurman, Gabri van derPluijm, Jacobus Burggraaf, Susanne Osanto |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Wiley
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/7f6f12eb65c74ad0b8cee9f1481033da |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
par: Nikolai A. Ognerubov
Publié: (2021) -
Advanced Therapeutic Options for Treatment of Metastatic Castration Resistant Prostatic Adenocarcinoma
par: Faiza Naseer, et autres
Publié: (2021) -
TRACING THE CRIMINAL POLICY ON CASTRATION AND COMMUNITY RESPONSE
par: Mompang L Panggabean
Publié: (2021) -
Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
par: Caffo O, et autres
Publié: (2016) -
A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer
par: Archibald M, et autres
Publié: (2016)